Quantcast

Latest Antipsychotic Stories

2014-03-13 23:01:16

The proposed rule could open the way for victims of generic drug side effects to file product liability lawsuits against their manufacturers. New York, New York (PRWEB) March 13, 2014 In light of the mounting litigation involving Risperdal and gynecomastia (http://www.risperdallawsuitcenter.com/risperdal-gynecomastia/ ), Bernstein Liebhard LLP notes that the U.S. Food & Drug Administration (FDA) is considering new regulations which would allow generic manufacturers to make changes to...

2014-03-12 23:00:43

John R. Freedy, MD, PhD, Associate Professor of Family Medicine, Medical University of South Carolina, Charleston, presented on Posttraumatic Stress Disorder. Andrea R. Gauld, PharmD, Assistant Professor, Department of Clinical and Administrative Sciences, Notre Dame of Maryland University School of Pharmacy, Baltimore, presented on Atypical Antipsychotic Drugs:Safe Use and Monitoring. Glendale, CA (PRWEB) March 12, 2014 Audio-Digest Foundation Announces the Release of Family Practice...

2014-03-11 23:33:34

A pharmaceutical product liability litigation firm, Carey Danis & Lowe, is currently investigating an alleged Risperdal side effect, male breast growth. In February, the law firm launched an online Risperdal information center. St. Louis, MO (PRWEB) March 11, 2014 The St. Louis pharmaceutical lawyers at Carey Danis & Lowe are currently investigating an alleged Risperdal side effect, male breast growth, medically termed gynecomastia. Carey Danis & Lowe represents plaintiffs who...

2014-03-06 12:27:53

NEW YORK, March 6, 2014 /PRNewswire/ -- As Risperdal gynecomastia lawsuits (http://www.risperdallawsuitcenter.com/) continue to be filed on behalf of individuals who suffered gynecomastia (male breast growth) and other complications due to their use of the atypical antipsychotic medication, Bernstein Liebhard LLP notes the publication of a new study examining the side effects associated with psychotropic medications like Risperdal. The research, which was presented this month at the...

2014-03-06 08:30:23

-- Significantly Higher Drug Exposure Achieved with Continued Tolerability -- SEATTLE, March 6, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the...

2014-03-04 23:28:40

Gordon & Doner is extending free consultations to patients who allegedly suffered serious health consequences after being prescribed the antipsychotic medication Risperdal WEST PALM BEACH, Fla (PRWEB) March 04, 2014 With litigation pending in the Court of Common Pleas, Philadelphia County, Pennsylvania (case no. 100300296,) South Florida law firm Gordon & Doner is now accepting injury claims and inquiries about the dangers of the antipsychotic medication, Risperdal. “Our goal is...

2014-03-04 23:25:04

The global market for drugs used to treat mental disorders was valued at $70.1 billion in 2012 and is estimated to have declined slightly to nearly $69 billion in 2013. BCC Research projects the market to grow to nearly $77.1 billion by 2018, and register a five-year compound annual growth rate of 2.3% from 2013 to 2018. Wellesley, Mass., (PRWEB) March 04, 2014 According to a new technical market research report Drugs for Treating Mental Disorders: Technologies and Global Markets, from...

2014-03-03 08:31:55

ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults MOUNTAIN VIEW, Calif., March 3, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced the U.S. commercial launch of ADASUVE(®) (loxapine) inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries Ltd., (NYSE: TEVA). ADASUVE is the first and only orally inhaled medicine for the acute...

2014-03-03 08:30:51

NEW YORK, March 3, 2014 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease....

High Dose Antidepressant Offers Some Hope For Alzheimer's Patients
2014-02-19 12:58:56

Brett Smith for redOrbit.com - Your Universe Online Agitation is a common symptom in patients with Alzheimer's disease and is associated with severe adverse consequences for both patients and caregivers. According to a new study published in JAMA, a high dose of the antidepressant citalopram considerably reduced agitation in patients with Alzheimer’s. However, the drug administered at this dose was also associated with mild adverse cognitive and cardiac effects – a sign that this...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related